Kush Abeysekera
LightNews LightNews
banner
kushabey.bsky.social
Kush Abeysekera
@kushabey.bsky.social
130 followers 170 following 9 posts
Consultant Senior Lecturer in Liver Disease Epidemiology & Public Health

University of Bristol | Bristol Royal Infirmary

COYG🔴⚪️
Posts Replies Media Videos
Reposted by Kush Abeysekera
ochoaallemantmd.bsky.social
🚨Check out our new study in @jhepatology.bsky.social ❗️

Using natural language processing to identify >350,000 patients with #steatosis, we demonstrated that cause-specific mortality differs between #MASLD #MetALD and #ALD

www.journal-of-hepatology.eu/article/S016...
Cause-specific mortality in patients with steatotic liver disease in the United States
Causes of death across steatotic liver disease (SLD) subtypes remain incompletely characterized in routine clinical practice. We aimed to quantify and compare cause-specific mortality in SLD.
www.journal-of-hepatology.eu
May 29, 2025 at 10:53 PM
kushabey.bsky.social
**Why public health matters for clinicians caring for patients with liver disease**

This short explainer crystallises the important issues clinicians and patients face, and how we can help! @easlnews.bsky.social #liverhealth #preventativehepatology

www.youtube.com/watch?v=L5ec...
An introduction to EASL's Policy, Public Health, and Advocacy Committee
YouTube video by EASL - Home of Hepatology
www.youtube.com
May 29, 2025 at 12:25 PM
Reposted by Kush Abeysekera
iandunt.bsky.social
Quite apart from anything else, this a major opportunity for UK higher education which we are currently doing our best to neutralise.
May 28, 2025 at 6:57 AM
Reposted by Kush Abeysekera
robfordmancs.bsky.social
If a government with over 400 seats and 4 years left to govern cannot summon the courage to level with the public on social care then I despair at the capacity of our political system to ever deliver the change we need.
May 11, 2025 at 6:14 PM
Reposted by Kush Abeysekera
robfordmancs.bsky.social
So if the Home Office wants to reduce student migration numbers it needs to explain why it considers British families paying more for uni and/or the largest employer in many red wall towns going under is a price worth paying to reduce a form of migration that bothers no one
April 8, 2025 at 7:58 AM
Reposted by Kush Abeysekera
bristolliverunit.bsky.social
A great trip to #ESGEDays2025 for Bristol Liver Unit where Drs Adamson, Portal, Hawken and Healey presented their work
April 5, 2025 at 9:27 AM
kushabey.bsky.social
Fantastic health inequalities in liver disease event in Birmingham, delighted to see Annie Archer discussing the experience in Bristol with Alright My Liver. Thanks to Ryan Buchanan and Kate Glyn-Owen for organising! Important (and difficult) discussions about how to move things forward.
March 27, 2025 at 1:16 PM
Reposted by Kush Abeysekera
liverepi.bsky.social
New paper from us in @jhepatology.bsky.social: www.journal-of-hepatology.eu/article/S016...
Causes of death in >13,000 persons with #MASLD - check it out #liversky. So proud of co-senior author Axel Wester and first author medical student Gabriel Issa for the work!
Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden
Data on cause-specific mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We aimed to determine the rate and risk of death from different causes in patients wit...
www.journal-of-hepatology.eu
March 24, 2025 at 7:51 PM
Reposted by Kush Abeysekera
erictopol.bsky.social
SGLT2 (sodium-glucose transporter) inhibitors are now recommended for all people with chronic kidney disease
www.acpjournals.org/doi/10.7326/... @annalsofim.bsky.social
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline | Annals of Internal Medicine
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatmen...
www.acpjournals.org
March 10, 2025 at 9:52 PM
Reposted by Kush Abeysekera
ebtapper.bsky.social
Hope, hurdles, and hazards

The role of statins in MASLD

a privilege to write this editorial with @NKimer

www.sciencedirect.com/science/arti...

On the terrific original article by @Dr_KMCoop @DeepikaDevuniMD

www.sciencedirect.com/science/arti...
Statins in Metabolic Dysfunction–Associated Liver Disease: Hope, Hurdles, and Biostatistical Hazards
www.sciencedirect.com
February 3, 2025 at 11:25 AM
Reposted by Kush Abeysekera
rashidlui.bsky.social
Check out the latest @amergastroassn.bsky.social guidelines on the prevention and treatment of hepatitis B reactivation now out in @gastroenterology.bsky.social

#MedSky #LiverSky #OncSky

www.gastrojournal.org/action/showP...
January 24, 2025 at 11:58 AM
Reposted by Kush Abeysekera
nejm.org
This paper described the groundbreaking, first gene-editing therapy for sickle cell disease to be approved by the FDA. We now have 2 approved stem cell therapies that can cure sickle cell disease. Revisit the paper: nej.md/33JG0cJ

#MedSky #Hematology
On this Day in 2021 Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease Visual representation of “CRISPR-Cas9” from the NEJM Illustrated Glossary. The NEJM identity sits at the bottom.
January 21, 2025 at 2:02 PM
Reposted by Kush Abeysekera
medicine.stitches.today
Autologous macrophage therapy appears safe and may reduce severe adverse events in cirrhosis patients, warranting further research.

by Brennan PN, MacMillan M (...) Forbes SJ et 19 al. in Nat Med #MedSky

📖 read the article:
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial - Nature Medicine
Results from the phase 2 MATCH01 clinical trial of autologous monocyte-derived macrophage therapy for liver cirrhosis revealed no liver-related severe adverse events or deaths in the treatment group.
www.nature.com
January 19, 2025 at 8:26 PM
Reposted by Kush Abeysekera
hpruebs.bsky.social
📰Fresh news for 2025!📰Alright My Liver? A qualitative service evaluation for early detection of liver disease in high-risk groups has been published. The pathway aims to diagnose #liverdisease earlier in the people most at risk.
Read more➡️ bit.ly/4h6KopA
#PublicHealth @bmj.com
Liver shaped icon. Text "Alright my liver"
January 7, 2025 at 10:19 AM
kushabey.bsky.social
I know I shouldn’t be surprised but why is a broadsheet peddling snake oil dressed up as liver wellness. I am however regretting not thinking of De-Liver-ence as my bluesky handle.

*** long sigh ***

www.thetimes.com/article/8b48...
Gulp! I took a £300 liver test after drinking Christmas dry
Festive indulgence is an occupational hazard for our deputy food editor, so who better to try a new year liver MoT?
www.thetimes.com
January 4, 2025 at 10:33 PM
Reposted by Kush Abeysekera
easlnews.bsky.social
👋Hello #Liversky!
🗞️Proud to see our EASL experts @debbieshawcross.bsky.social , @ahmedelsharkawy.bsky.social, and Philip Newsome featured in The Guardian with advice on liver health.
Indulged during the holidays? It's not too late to give your liver some love!💚
www.theguardian.com/lifeandstyle...
January 3, 2025 at 9:18 AM
Reposted by Kush Abeysekera
adhanda.bsky.social
Do read my comment piece with @tom-marjot.bsky.social on NoLo alcohol 👇🏾
natrevgastrohep.nature.com Nature Reviews Gastroenterology & Hepatology @natrevgastrohep.nature.com · Jan 3
JAN ISSUE | COMMENT

Alcohol-free and low-strength drinks: friend or foe?

www.nature.com/articles/s41...

#Liversky #Gastrosky
A quote from an article about alcohol-free drinks stating: "alcohol drinkers are twice as likely to consume alcohol-free drinks than non-drinkers"
January 3, 2025 at 9:46 PM
Reposted by Kush Abeysekera
tom-marjot.bsky.social
#LiverSky

Useful tip...

There's no 'bookmark' function in Bluesky currently. But there is a nice work-around:

1) Reply to the post of interest with a📌emoji
2) Click on this link bsky.app/profile/did:...
3) Click 'Pin to Home'

This will collate📌posts in a tab on your home screen + ⬆️ engagement.
November 26, 2024 at 12:11 PM
Reposted by Kush Abeysekera
nnekauferemd.bsky.social
Do conversations about prognosis (defined as "conversation with your hepatologist about the likely outcome of your liver disease over time") cause patients w/ cirrhosis to lose hope?

Simple answer: No

Work led by🌟@donlan_john in CGH @amergastroassn.bsky.social https://buff.ly/4i1R6OM #LiverSky
November 24, 2024 at 2:57 PM
Reposted by Kush Abeysekera
ebtapper.bsky.social
I recommend this review on muscle cramps in #cirrhosis

Cramps are common and are the number one symptom priority for many patients

doi.org/10.1111/apt....

But ….
Management of Muscle Cramps in Patients With Cirrhosis: A Systematic Review of Randomised Controlled Trials
Despite the prevalence and quality of life impact cramps have on patients with cirrhosis, no widely used clinical practice guidelines on management exist. Our systematic review, focusing only on rand...
doi.org
November 24, 2024 at 9:32 PM